It's flu vaccine season, and as reports of H7N9 bird flu cases rise in China, Novartis ($NVS) and Novavax ($NVAX) both say they're now able to develop new immunizations within months of a viral strain's identification and sequencing. Report
It's flu vaccine season, and as reports of H7N9 bird flu cases rise in China, Novartis ($NVS) and Novavax ($NVAX) both say they're now able to develop new immunizations within months of a viral strain's identification and sequencing. Report